Corticotropin-Releasing Hormone

Overview

Corticotropin-releasing hormone (CRH, also known as corticotropin-releasing factor or CRF) is a 41-amino acid neuropeptide that serves as the primary initiator of the hypothalamic-pituitary-adrenal (HPA) axis. First isolated from ovine hypothalamus by Vale and colleagues in 1981, CRH represents the principal neuroendocrine mediator linking psychological and physiological stress to endocrine output.

Structure and Biosynthesis

CRH is synthesized as part of a larger precursor molecule, prepro-CRH, which undergoes proteolytic processing to yield the mature 41-residue peptide. The sequence is highly conserved across mammalian species, with the active core residing in residues 6-33. CRH adopts an amphipathic alpha-helical conformation in solution, which is essential for receptor binding. The peptide is secreted from parvocellular neurons of the paraventricular nucleus (PVN) of the hypothalamus into the hypophyseal portal circulation.

Receptors and Signaling

CRH exerts its effects through two G-protein-coupled receptors: CRHR1 (CRF1) and CRHR2 (CRF2). CRF1 is widely distributed in the anterior pituitary, cortex, cerebellum, and limbic structures, mediating the endocrine and behavioral responses to stress. CRF2 is predominantly expressed in the hypothalamus, septum, and choroid plexus, modulating satiety, anxiety, and cardiovascular function. Both receptors signal through Gs-coupled pathways, elevating intracellular cAMP and activating protein kinase A (PKA).

Physiological Functions

The primary function of CRH is to stimulate the release of adrenocorticotropic hormone (ACTH) from corticotrophs in the anterior pituitary. ACTH then acts on the adrenal cortex to promote cortisol biosynthesis and secretion. Beyond its endocrine role, CRH acts as a neuromodulator in the central nervous system, influencing arousal, anxiety-like behavior, feeding, and immune function. CRH-containing neurons project widely throughout the brain, including to the locus coeruleus, amygdala, and periaqueductal gray.

Clinical Significance

Dysregulation of CRH signaling is implicated in major depressive disorder, anxiety disorders, and post-traumatic stress disorder (PTSD). Elevated CSF CRH levels have been consistently observed in depressed patients, and antidepressant treatments reduce CRH expression. CRH antagonists are under investigation as potential anxiolytics. Inflammatory bowel disease and chronic pain syndromes also involve aberrant CRH signaling in peripheral tissues. The CRF2 selective agonist urocortin 2 shows promise in regulating energy homeostasis and cardiac function.